Sep 7, 2022 Press Releases
PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...
Sep 6, 2022 Press Releases
PDF Version Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition element This novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for the enhanced clearance of tissue amyloid SAN...
Sep 6, 2022 Press Releases
PDF Version AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleen AT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrils AT-02 binds potently to multiple types of amyloid including ATTR, AL, and ALECT2 SAN FRANCISCO, Calif....
Aug 22, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – August 22, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that new data across the Company’s...
Aug 8, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – August 8, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...
